Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $5.1 million.

  • Enanta Pharmaceuticals' Net Cash Flow fell 8909.29% to $5.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$47.5 million, marking a year-over-year decrease of 20698.85%. This contributed to the annual value of -$5.5 million for FY2025, which is 8848.93% up from last year.
  • As of Q4 2025, Enanta Pharmaceuticals' Net Cash Flow stood at $5.1 million, which was down 8909.29% from -$12.5 million recorded in Q3 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Net Cash Flow peaked at $52.6 million during Q3 2021, and registered a low of -$72.5 million during Q2 2021.
  • Moreover, its 5-year median value for Net Cash Flow was -$156500.0 (2022), whereas its average is -$745300.0.
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 51343.13% in 2021, then crashed by 246662.9% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Net Cash Flow (Quarter) stood at $41.9 million in 2021, then tumbled by 104.23% to -$1.8 million in 2022, then plummeted by 2466.63% to -$45.5 million in 2023, then soared by 203.65% to $47.1 million in 2024, then crashed by 89.09% to $5.1 million in 2025.
  • Its Net Cash Flow stands at $5.1 million for Q4 2025, versus -$12.5 million for Q3 2025 and -$15.4 million for Q2 2025.